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Abstract
Only few studies document longer periods of fasting in large cohorts including non-obese
participants. The aim of this study was to document prospectively the safety and any
changes in basic health and well-being indicators during Buchinger periodic fasting within a
specialised clinic. In a one-year observational study 1422 subjects participated in a fasting
program consisting of fasting periods of between 4 and 21 days. Subjects were grouped in
fasting period lengths of 5, 10, 15 and 20±2 days. The participants fasted according to the
Buchinger guidelines with a daily caloric intake of 200–250 kcal accompanied by a moder-
ate-intensity lifestyle program. Clinical parameters as well as adverse effects and well-being
were documented daily. Blood examinations before and at the end of the fasting period com-
plemented the pre-post analysis using mixed-effects linear models. Significant reductions in
weight, abdominal circumference and blood pressure were observed in the whole group
(each p<0.001). A beneficial modulating effect of fasting on blood lipids, glucoregulation and
further general health-related blood parameters was shown. In all groups, fasting led to a
decrease in blood glucose levels to low norm range and to an increase in ketone bodies lev-
els (each p<0.001), documenting the metabolic switch. An increase in physical and emo-
tional well-being (each p<0.001) and an absence of hunger feeling in 93.2% of the subjects
supported the feasibility of prolonged fasting. Among the 404 subjects with pre-existing
health-complaints, 341 (84.4%) reported an improvement. Adverse effects were reported in
less than 1% of the participants. The results from 1422 subjects showed for the first time
that Buchinger periodic fasting lasting from 4 to 21 days is safe and well tolerated. It led to
enhancement of emotional and physical well-being and improvements in relevant cardiovas-
cular and general risk factors, as well as subjective health complaints.
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Introduction
There are a growing number of recent publications on intermittent fasting (IF), generally last-
ing 16 to 48 hours, and calorie restriction (CR). Periodic fasting (PF), recently defined as last-
ing from 2 to as many as 21 or more days, is less studied in humans, especially for periods
longer than 4 days [1, 2]. Results show that lifespan and healthspan are prolonged in several
animal models by fasting and CR [2–7] and that parameters of age-related diseases are
improved in humans [5, 8, 9]. Fasting leads to pronounced metabolic changes: The shift from
carbohydrates and glucose to fatty acids and ketones as the major cellular fuel source for body
and brain seems to play a key role. It has recently been referred to as intermittent metabolic
switching (IMS) and glucose-to-ketone (G-to-K) switch. The reverse step–ketone-to-glucose
(K-to-G) switch–happens upon refeeding [2]. The G-to-K switch includes reduction in blood
glucose, insulin and IGF-1 levels, depletion or reduction of glycogen stores, and an increase in
lipolysis and ketogenesis [2, 5, 10]. Fasting has been shown to induce differential cellular stress
resistance [11] and autophagy [12, 13], as well as triggering the synthesis of detoxification
enzymes [9, 14]. Fasting seems to modify the intestinal microbiome [9, 15]. It also leads to
changes in the intestinal mucosal walls in rats [16] and to pronounced neuroendocrine adapta-
tion processes [2, 17]. Finally, in the K-to-G switch, fasting has been found to activate stem
cells and multiple system regeneration in the refeeding period [4, 18, 19] and to increase the
mitochondrial biogenesis in neurons and other body cells [2, 9].
Long periods of fasting, lasting several days to several weeks, are physiologic, e.g. during
seasons of low sun exposure, and are still part of the life of most animals [20, 21] as well as of
humans living without food conservation technologies [22].
Fasting periods with various patterns are found in most religions [23]. For instance, Ramadan
intermittent fasting was linked with improvements in cardiometabolic risk factors [24]. Further-
more, morbid obesity and associated diseases were treated in the 1960s with long periods of fast-
ing that were termed the “zero calorie diet” [25, 26]. In exceptional circumstances these periods
could last up to 249 days or more [27, 28]. A medical program of periodic fasting developed by
the German physician Otto Buchinger to treat obesity and metabolic and inflammatory patholo-
gies is well-known in central Europe [29–31]. The therapeutic effects of Buchinger periodic fasting
are documented in small studies on overweight [32], blood pressure [33], metabolic syndrome
[34], fibromyalgia [35], chronic pain syndromes [36] and the enhancement of quality of life [37].
The effects of repeated cycles of Buchinger fasting have also been reported [38, 39].
We are not aware of large studies on PF including normal weight or moderately obese sub-
jects and focused on safety and tolerability. In the present observational study, we documented
prospectively the safety, general health-related outcomes and well-being of 1422 subjects. They
fasted for periods between 4 to 21 days under medical supervision according to the Buchinger
fasting program, as described in peer-reviewed guidelines [31]. The fasting took place in a facil-
ity specialized in therapeutic fasting, the Buchinger Wilhelmi clinic (BWC) in Germany. The
protocol involved daily clinical monitoring, intake of 2–3 L of water per day and 250 kcal of
food, as well as a multi-disciplinary program including health education and physical activity.
The aim of this study was to assess for the first time prospectively the safety, therapeutic effi-
ciency and effects on well-being of Buchinger periodic fasting in a large cohort.
Materials and methods
Ethics
This observational and prospective study was approved by the medical council of Baden-Würt-
temberg and the Ethics Committee of the Charité-University Medical Center, Berlin
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(application number: EA4/054/15) on 5 May 2015. The study protocol was registered in the
German Clinical Trials Register (DRKS-ID: DRKS00010111). The authors confirm that all
ongoing and related trials for this intervention are registered. At the time of obtaining the ethi-
cal approval by the German authorities it was not mandatory to register an observational
study. Only randomized clinical trials were clearly recommended to register. Nevertheless, we
decided to register this observational study (on 3 June 2016).
Participants were enrolled after giving their written informed consent between 1 January
and 31 December 2016. The study was conducted in the BWC in Überlingen (Germany) in
accordance with the principles of the Declaration of Helsinki. The follow-up was completed
between 26 January 2016 and 18 December 2017.
Participants
Our study on Buchinger fasting during periods of 4 to 21 days included 1422 subjects. They
were selected out of a total of 3929 subjects who were admitted to the BWC and fulfilled the
following criteria: they had a clinic stay of at least 10 nights and signed the informed written
consent at the beginning of the inpatient stay after confirming that they would not participate
in another study. Subjects were aged between 18–99 years and had no predefined contraindi-
cation to Buchinger fasting (e.g. cachexia, anorexia nervosa, advanced kidney, liver or cerebro-
vascular insufficiency, dementia or other severely debilitating cognitive disease and no existing
pregnancy or lactation period) [31]. Furthermore, blood must have been collected on the pre-
cise days defined in the protocol (S2 and S3 Text). We excluded subjects who were prescribed
other diets than fasting according to predefined criteria as well as those who could not follow
the study procedures due to an inability to speak German, English or French. A flow chart
reflecting the selection procedure is given in Fig 1.
The subjects came voluntarily to the BWC for preventive or therapeutic reasons. They
selected established programs of 5, 10, 15 and 20 fasting days, which are reflected in the 4
groups (F5d, F10d, F15d, F20d). The main personal intentions for the fasting intervention
were reduction of cardiovascular risk factors, weight loss in case of obesity and relief of general
health problems such as inflammatory diseases, distress and exhaustion. In case of prescribed
drug intake, the dosage was adapted during the stay by the 8 physicians of the clinic, who
examined all participants 2 to 3 times per week. The subjects had a wide diversity of national
and cultural backgrounds. The majority of them came from upper social classes and had high
education levels.
Fasting program
All subjects fasted according to the guidelines of the Buchinger fasting therapy [31] under
daily supervision of nurses and specialized physicians. On the day before the beginning of the
fast, the participants were given a 600 kcal vegetarian diet divided into 3 meals of either rice
and vegetables or fruits, according to individual preference. To initiate the fasting period, the
intestinal tract was emptied through the intake of a laxative (20–40 g NaSO4 in 500 ml water).
During fasting all subjects were asked to drink 3 L of water or non-caloric herbal teas daily
with an optional portion of 20 g honey. Additionally, an organic freshly squeezed fruit or vege-
table juice (250 ml) was served at noon and a vegetable soup (250 ml) in the evening, leading
to an average total calorie intake of 200–250 kcal and 25–35 g of carbohydrates per day. At the
beginning of the fasting period the subjects entered a program of light physical exercise alter-
nating with rest and individual mild non-physical treatments like hydrotherapy or physiother-
apy. The exercise program consisted of light to moderate intensity outdoor walks and group
gymnastics. The whole program was led by certified trainers. During the fasting period an
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enema or, if preferred by the patient, a mild laxative was applied every second day in order to
remove intestinal remnants and desquamated mucosal cells. On the last day of fasting, food
was stepwise reintroduced during an average of 4 days, with an ovo-lacto-vegetarian organic
diet progressively increasing from 800 to 1600 kcal/day.
Measurements
To document safety as well as health benefits and well-being during a prolonged periodic fast-
ing program, we performed the predefined following measurements at baseline (pre-) and at
the completion of fasting (post-). Before starting the fast all subjects went through a thorough
physical examination and their medical history was documented.
Well-being, ketone bodies, mild symptoms and any changes in major health complaints
were self-reported under supervision. The results were daily noted in a questionnaire (S4, S5,
S6 Text). A total of 1311 subjects out of the 1422 returned the completed questionnaire.
Weight, abdominal circumference, blood pressure and pulse. Clinical data were col-
lected by the physicians. Trained nurses documented every morning according to a standard-
ized protocol the body weight of the participants wearing standard clothing (Seca 704, Seca,
Fig 1. Flow chart of the selection procedure of study participants.
https://doi.org/10.1371/journal.pone.0209353.g001
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Hamburg, Germany). Blood pressure and pulse were measured after a pause, once at the non-
dominant arm in sitting position (upper arm blood pressure monitor, boso Carat professional,
BOSCH + SOHN GmbH u. Co. KG, Jungingen, Germany). Height was assessed with seca 285
(Seca, Hamburg, Germany) and abdominal circumference was determined with a measuring
tape mid-way between the lowest rib and the iliac crest (openmindz GmbH, Heidelberg,
Germany).
Well-being. To evaluate well-being, the participants self-reported daily their physical
(PWB) and emotional well-being (EWB) on numeric rating scales from 0 (very bad) to 10
(excellent), under nurses’ supervision. The aim was to document the tolerability of the fasting
program.
In a pre-study sample, we evaluated the acceptance of validated questionnaires to assess
well-being within the patient population of the BWC, but found that they were regarded as too
time-consuming in comparison with the numeric rating scales. To avoid drop-out and missing
data, we therefore decided to use numeric rating scales.
Ketone bodies. The subjects self-measured the semi-quantitative concentration of ketone
bodies in the first morning urine using Ketostix (Bayer AG, Leverkusen, Germany), which
reacts according to the concentration of acetoacetic acid.
Mild symptoms and adverse effects. The Buchinger periodic fasting program was con-
tinuously monitored for safety and supervised by the medical staff: mild symptoms were
reported daily by means of a multiple choice questionnaire, completed by the subjects under
the supervision of nurses. This questionnaire listed the 19 most frequent mild symptoms that
are observed in BWC and mentioned in the guidelines of the Buchinger fasting therapy [31].
We considered a mild symptom as being relevant when it was mentioned at least 3 times. In
addition to the listed symptoms, the medical staff reported further mild symptoms that we cat-
egorized as “observed symptoms”. Furthermore, occasional adverse effects (AE) were docu-
mented by the physicians.
Major health complaint. A self-evaluation of health status was undertaken at the end of
the stay: the subjects were asked to self-rate any changes in their major health complaint (in
cases in which they indicated one at the begin of the fast) during the fasting intervention on a
visual numeric scale from 0 (much worse) to 7 (much better).
Blood analysis. A blood analysis was taken according to international methods (see
below): (lipid parameters: total cholesterol [TC], triglycerides [TG], high-density lipoprotein
[HDL-C], low-density cholesterol [LDL], LDL-C/HDL-C ratio [LDL/HDL-ratio]; glycaemia:
blood glucose and glycated haemoglobin [HbA1c]; blood count: leukocytes, erythrocytes, hae-
moglobin, haematocrit, mean cell volume [MCV], mean corpuscular haemoglobin [MCH],
mean corpuscular haemoglobin concentration [MCHC], thrombocytes; coagulation: interna-
tional normalized ratio [INR], Quick, partial thromboplastin time [PTT]; liver function:
serum glutamic oxaloacetic transaminase [GOT], serum glutamate pyruvate transaminase
[GPT], serum gamma-glutamyl transferase [GGT], alkaline phosphatase [AP]; inflammatory
biomarkers: C-reactive protein [CRP], erythrocyte sedimentation rate [ESR] after 1 and 2
hours; renal function: uric acid, urea and creatinine and electrolytes: sodium [Na], potassium
[K], calcium [Ca], magnesium [Mg]).
Laboratory examinations
Blood samples were collected twice, namely before the start of the fasting (thereafter referred
as baseline values) and at the end of the fasting period. They were collected by trained medi-
cal-technical assistants between 7.30 and 9.30 am and drawn into EDTA (S-Monovette 2.7 ml
K3 EDTA), citrate (S-Monovette 3 ml 9NC, Citrate 3.2% [1:10]) and blood sedimentation
Safety, health and well-being during periodic fasting
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tubes (S-Sedivette 3.5 ml 4NC, ESR/Citrate Buffer [1:5]), that were shaken gently after filling.
Additionally, serum tubes including serum gel with clotting activator (S-Monovette 9 ml
Z-Gel) were used and stored upright for 30 min until coagulation, with subsequent centrifuga-
tion at 3920 g (5000 rpm) for 10 min at room temperature. All tubes were manufactured by
Sarsteadt AG & Co. (Nürnbrecht, Germany).
The ESR was assessed within a period of 4 hours after blood collection and determined
after 1 and 2 hours of blood sedimentation. All further analyses were performed at MVZ Labor
Ravensburg, according to the manufacturer’s instruction, in a fully- automated laboratory.
Blood cell count (leukocytes, erythrocytes, haemoglobin, MCV, MCH, MCHC, thrombocytes)
was measured using the blood analyser Sysmex XN-9000 (Sysmex Europe GmbH, Norder-
stedt, Germany). Coagulation parameters (INR, Quick, PTT) were assessed on ACL Top (Wer-
fen, Kirchheim, Germany). The liver enzymes (GOT, GPT, GGT, AP), kidney parameters
(urea, creatinine, uric acid), lipid parameters (TC, TG, HDL-C, LDL-C, LDL/HDL ratio), elec-
trolytes (Na, K, Ca), glucose and CRP were analysed with ADVIA 2400 (Siemens Healthcare
GmbH, Erlangen, Germany). The HbA1c was assessed with TOSOHTM (Bio-Rad Laboratories
GmbH, München, Germany) and Mg with ICP-MS 7700x series (Agilent, Waldbronn,
Germany).
Data and statistical analysis
Participants were divided into four groups according to the duration of their fasting period
(Fig 1): F5d underwent a fasting period of 5±2 days, with an average of 5.4 (n = 695), F10d
underwent a fasting period of 10±2 days, with an average of 8.6 (n = 530), F15d underwent a
fasting period of 15±2 days, with an average of 14.1 (n = 196) and F20d underwent a fasting
period of 20±2 days, with an average of 20.1 (n = 37). Between-group differences at baseline
were tested using a one-way ANOVA test followed by Tukey’s post-hoc tests.
We tested the effect of fasting, while taking into account the sex and fasting duration group
effects, by using a multistep parsimonious statistical approach. First, for each outcome the
effect of fasting was assessed by using mixed linear models taking repeated measurements
among subjects into account, with fasting intervention, fasting duration group, sex, fasting
duration group-by-fasting-intervention, fasting intervention-by-sex, sex-by-fasting duration
group and baseline values of the outcome (pre-fasting) as fixed effects. For each outcome, the
covariance structures was selected among three (compound symmetry (CS), autoregressive
(AR(1)) and variance components (VC)) using the Bayesian information criteria (BIC). In a
last step the interaction effects that were not significant, were removed from the model to
obtain a more parsimonious model. To simplify the presentation of the results, sex differences
are presented in figures only when the fasting-intervention-by-sex effect was significant. To
take into account the multiple tests performed on this dataset, significance was set at a conser-
vative level of p<0.01.
Data are shown as mean±standard error of the mean (SEM), if not indicated otherwise. Sta-
tistical analyses were performed with SAS version 9.4 (SAS Institute, Cary, USA). Graphs were
generated using GraphPad Prism version 6 for Windows (GraphPad Software, La Jolla Califor-
nia USA).
Results
General parameters
The baseline characteristics of the 1422 adult participants are shown in Table 1. Mean age was
55.4±0.4 with 59.1% women and 40.9% men. In total 63.4% of the subjects were non-obese
(BMI<30). Grade I obesity (30�BMI<35) was present in 19.5% and grade II or higher
Safety, health and well-being during periodic fasting
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(BMI�35) in 10.3%. Subjects who chose to fast on average for 20 days (F20d) had the highest
baseline body mass index (BMI), the highest abdominal circumference (waist), and largest
weight reduction (-8.6±0.3 kg) (each p<0.001). Men had a higher mean BMI at baseline
(Table 1).
Weight, abdominal circumference and blood pressure
As expected, weight and BMI showed a significant decrease (fasting intervention: p<0.001) in
all 4 groups (S1 Table). The weight loss increased with the fasting period length and varied
between 3.2±0.0 kg for F5d and 8.6±0.3 kg for F20d (fasting duration group-by-fasting inter-
vention: p<0.001). Abdominal circumference also decreased significantly (fasting interven-
tion: p<0.001). The reduction varied between 4.6±0.1 cm for F5d and 8.8±0.8 cm for F20d
(fasting duration group-by-fasting intervention: p<0.001). Weight and abdominal circumfer-
ence reduction were significantly higher (fasting-intervention-by-sex: each p<0.001) in men
in all groups (Fig 2A and 2B), compared with women.
Baseline values of systolic blood pressure (SBP) and diastolic blood pressure (DBP) were
higher in the groups fasting longer (Fig 3A and 3B). The mean values for the whole cohort
decreased significantly from 131.6±0.7 to 120.7±0.4 for SBP (fasting intervention: p<0.001)
and from 83.7±0.4 to 77.9±0.3 for DBP (fasting intervention: p<0.001). The reduction of SBP
and DBP was greater in the groups who fasted longer (fasting duration group-by-fasting inter-
vention: each p<0.001) without gender difference (Fig 3A and 3B), stabilizing for the whole
Table 1. Baseline characteristics of the subjects.
All F5d F10d F15d F20d
Days (d) 5±2 10±2 15±2 20±2
Subjects, n (%) 1422 (100.0) 659 (46.3) 530 (37.3) 196 (13.8) 37 (2.6)
Men (%) 581 (40.9) 278 (42.2) 214 (40.4) 76 (38.8) 13 (35.1)
Women (%) 841 (59.1) 381 (57.8) 316 (59.6) 120 (61.2) 24 (64.9)
Age, years 55.4±0.4 54.2±0.5 b,c 56.3±0.6 a 56.4±0.9 a 56.4±2.3
Fasting length (days) 8.2±0.1 5.4±0.0 b,c,d 8.6±0.0 a,c,d 14.1±0.1 a,b,d 20.1±0.2 a,b,c
Waist, cm 94.0±0.4 91.3±0.6 b,c,d 94.8±0.7 a,c,d 98.3±1.2 a,b,d 106.3±2.8 a,b,c
Weight, kg 82.0±0.5 79.3±0.8 b,c,d 82.7±0.9 a,c,d 86.6±1.6 a,b,d 96.7±4.0 a,b,c
BMI, kg/m2 28.2±0.2 27.2±0.2 b,c,d 28.5±0.3 a,c,d 29.7±0.4 a,b,d 33.6±1.1 a,b,c
BMI<25, n (%) 404 (28.4) 227 (56.2) 133 (32.9) 41 (10.1) 3 (0.7)
25�BMI<30, n (%) 497 (35.0) 232 (46.7) 199 (40.0) 61 (12.3) 5 (1.0)
BMI�30, n (%) 425 (29.9) 155 (36.5) 160 (37.6) 84 (19.8) 26 (6.1)
BMI men, kg/m2 30.0±0.2 29.2±0.3 30.3±0.3 31.3±0.7 34.0±1.5
BMI<25, n (%) 74 (12.7) 46 (62.2) 18 (24.3) 10 (13.5) 0 (0.0)
25�BMI<30, n (%) 231 (39.8) 117 (50.6) 92 (39.8) 20 (8.7) 2 (0.9)
BMI�30, n (%) 230 (39.6) 94 (40.9) 87 (37.8) 40 (17.4) 9 (3.9)
BMI women, kg/m2 27.0±0.2 25.7±0.2 27.3±0.3 28.7±0.5 33.3±1.4
BMI<25, n (%) 330 (39.2) 181 (54.8) 115 (34.8) 31 (9.4) 3 (0.9)
25�BMI<30, n (%) 266 (31.6) 115 (43.2) 107 (40.2) 41 (15.4) 3 (1.1)
BMI�30, n (%) 195 (23.2) 61 (31.3) 73 (37.4) 44 (22.6) 17 (8.7)
Subjects were divided into 4 groups according to the fasting lengths: 5, 10, 15 and 20±2 days. Significant differences between the groups are indicated as
a, p<0.05 versus F5d
b, p<0.05 versus F10d
c, p<0.05 versus F15d
d, p<0.05 versus F20d. BMI, body mass index. Data are presented as mean±SEM.
https://doi.org/10.1371/journal.pone.0209353.t001
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cohort around 120/78 mm Hg (S1 Table). We did not observe significant changes in heart rate
during fasting in the whole group (S1 Table).
Well-being
Baseline values of emotional well-being (EWB) and physical well-being (PWB) were lower in
the groups that fasted longer. This suggests that subjects choosing longer fasting periods had
lower emotional and physical self-ratings at baseline than the ones who selected shorter peri-
ods of fast. EWB as well as PWB were both significantly enhanced in the course of the fast
(fasting intervention: each p<0.001) (S1 Table). There is no difference between genders for
those parameters (Fig 4A and 4B). All groups reached similar increased values of well-being at
the end of their stay.
Ketone bodies
Acetoacetic acid, reflecting ketosis, increased significantly from baseline to the end of fast (fast-
ing intervention: p<0.001), suggesting a plateau value reached after 5 days. Men had higher
scores of acetoacetic acid than women (fasting intervention-by-sex: p<0.001) (S1 Table).
Mild symptoms and adverse effects
The safety of the Buchinger fasting program was assessed by collecting daily all self-reported
and observed mild symptoms (Table 2). Of the 1311 participants who returned the filled ques-
tionnaire, 0.35% reported muscular cramp, which was the least frequent mild symptom, and
14.94% sleep disturbances, which was the most frequent mild symptom. As shown in S1 Fig.
Fig 2. Changes in weight (A) and abdominal circumference (B) according to the length of fast and gender.
https://doi.org/10.1371/journal.pone.0209353.g002
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the incidence of mild symptoms like muscle pain, sleep disturbances, headaches, and hunger
occurred mainly in the first days of the fast.
No fatalities or permanent adverse effects were observed. Two subjects had to be admitted
to hospital. A 75-year old man with known coronary artery disease had on the 9th fasting day a
non-ST segment elevation myocardial infarction and received uncomplicated percutaneous
coronary intervention. After 3 days in the hospital he returned to BWC. The second case was a
67-year old woman who had a one-day hospitalisation because of vomiting with dizziness and
diarrhoea on the 4th fasting day. After returning to BWC she received an 800 kcal/d diet. The
other AE were transitory and did not lead to an interruption of the fasting therapy. AE
(Table 2) such as cardiac arrhythmia were low-grade, transitory and could be treated uncom-
plicatedly without stopping the fasting. The same applied to transitory hypoglycaemia. We also
observed one case of gout attack in a patient treated previous to the fasting with allopurinol for
hyperuricemia and frequent gout attacks. He was able to be symptomatically treated and went
on fasting.
Major health complaint
To document the effects of the Buchinger fasting program on their health we asked the partici-
pants to self-report if they had a major health complaint before the fasting and how this condi-
tion had been influenced by the fast. A group of 404 subjects out of the 1311 who returned the
self-report (S2 Fig) mentioned having a major health complaint previous to the fasting. They
were asked to evaluate the changes after the fasting. In 84.4% of the 404 subjects the major
health complaint had much improved, 8.7% reported that it remained unchanged and 6.9%
reported a worsening.
Fig 3. Changes in systolic (A) and diastolic blood pressure (B) according to the fasting length.
https://doi.org/10.1371/journal.pone.0209353.g003
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Blood lipids and glycaemia
We assessed the impact of the Buchinger fasting program on metabolism by analysing several
blood parameters (S2 Table).
The lipid values are indicated in S2 Table and Fig 5. At baseline, TG values of women were
lower than the values of men. Fasting reduced TG levels by 0.44 mmol/L on average (fasting
intervention: p<0.001) (S2 Table). TG levels at the end of the fasting were similar in all groups,
suggesting a floor effect (Fig 5A). The decrease in TC was significant (fasting intervention:
p<0.001) and higher in the groups who fasted for longer (fasting duration group-by-fasting
intervention: p<0.001). Fig 5B indicates that F15d and F20d had similar post-values. There
was no difference in TC changes during fasting between men and women. Baseline HDL-C
values were higher in women (Fig 5C). HDL-C decreased significantly (fasting intervention:
p<0.001). The reduction was higher in the groups that fasted longer (fasting duration group-
by-fasting intervention: p<0.001) and in women compared to men (fasting intervention-by-
sex: p<0.001). LDL-C decreased significantly (fasting intervention: p<0.001) (Fig 5D) and
again the decrease was higher in the groups that fasted longer (fasting duration group-by-fast-
ing intervention: p<0.001). Gender differences for LDL-C were not significant. The LDL/
HDL ratio was not influenced by fasting.
The blood glucose parameters are given in S2 Table and Fig 6. Baseline values for glucose
were higher in men compared to women (Fig 6). The glucose values decreased significantly
(fasting intervention: p<0.001) without differences between the fasting period lengths and sta-
bilized at an average of 4.7 mmol/L (S2 Table). Fig 6B shows the significant decrease in HbA1c
(fasting intervention: p<0.001), which varied between a decrease of 1.2±0.1 for F5d and 2.6
±0.5 mmol/mol for F20d (fasting duration group-by-fasting intervention: p<0.001).
Fig 4. Changes in emotional (A) and physical well-being (B) during fasting. Self-recorded data of a 0–10 numeric rating scale for a total of 1074
volunteers are shown.
https://doi.org/10.1371/journal.pone.0209353.g004
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Blood count
Table 3 shows the impact of fasting on blood count. Leucocytes decreased significantly in all
groups (fasting intervention: p<0.001) with stronger reduction in the groups who fasted lon-
ger (fasting duration group-by-fasting intervention: p<0.001) and without statistical signifi-
cance between men and women. Erythrocytes showed an increase (fasting intervention:
p<0.001) of an average of 0.06 x106/μl in all groups and steadied at around 4.82x106/μl. Hae-
moglobin showed also an increase (fasting intervention: p<0.001) of about 0.1 mmol/L that
was independent of the fasting length. Haematocrit was not influenced by fasting. Thrombo-
cytes showed a significant reduction (fasting intervention: p<0.001) during fasting by a mean
of 6.6±0.7x103/μl, with gender difference (fasting intervention-by-sex: p<0.001) and influence
of the fasting length (fasting duration group-by-fasting intervention: p<0.001).
Coagulation
Table 4 shows changes in blood coagulation parameters, liver function, inflammatory parame-
ters, kidney function and electrolytes. INR and PTT increased (fasting intervention: each
p<0.001) and Quick value decreased (fasting intervention: p<0.001) significantly during fast-
ing. The fasting period length had a significant influence on the coagulation parameters (fast-
ing duration group-by-fasting intervention: each p<0.001) and more pronounced changes
were observed in groups of longer fasting periods.
Table 2. Mild symptoms and adverse effects (AE).
Mild symptoms (self-reported) n % Mild symptoms (observed) n %
Sleep Disturbance 169 14.94 Dizziness 2 0.14
Fatigue 155 13.70 Eczema 2 0.14
Dry Mouth 100 8.84 Bleeding gums 1 0.07
Back Pain 84 7.43 Hyperventilation 1 0.07
Hunger 77 6.81 Outbreak of infection 1 0.07
Bad Breath 61 5.39 Pleuropneumonia 1 0.07
Headache 61 5.39 Tetany 1 0.07
Muscle Pain 49 4.33 Visual disorder 1 0.07
Abdominal Bloating 47 4.16
Diarrhoea 38 3.36
Sensitivity to Cold 33 2.92 AE n %
Cravings 29 2.56 Cardiac arrhythmia 3 0.21
Vertigo 28 2.48 Hyponatremia 3 0.21
Blurred Vision 23 2.03 Hospitalisation 2 0.14
Restless Legs 23 2.03 Hypoglycaemia 2 0.14
Skin Rash 19 1.68 Hypokalaemia 1 0.07
Nausea 13 1.15 Gout 1 0.07
Palpitation 13 1.15 Vomiting 1 0.07
Dyspepsia 12 1.06 Spasmodic abdominal pain 1 0.07
Muscular cramp 4 0.35
Out of the total of 1422 a group of 1311 subjects completed and returned the daily questionnaire to self-record mild symptoms. In contrast to the observed symptoms
and AE, self-reported mild symptoms were recorded if a particular symptom was experienced by the same person more than 3 times during the fasting period. The
observed symptoms and AE were documented during the daily nurse visit and/or the medical visit for all subjects. The same subject could mention more than one
symptom or AE.
https://doi.org/10.1371/journal.pone.0209353.t002
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Liver function
Regarding liver function, GOT and GPT levels rose significantly during the course of the fast
(fasting intervention: each p<0.001) without difference between groups. The values at baseline
and at the end remained within norm ranges (<0.8 μkat/L) increasing for GOT in average
from 0.4 to 0.6 μkat/L and GPT from 0.5 to 0.7 μkat/L. GGT levels decreased significantly
from a mean of 0.6 to 0.4 μkat/L (fasting intervention: p<0.001). AP showed a significant
decrease (fasting intervention: p<0.001), more pronounced in the groups that fasted longer
(fasting duration group-by-fasting intervention: p<0.001), with a slight dependence on gender
(fasting intervention-by-sex: p = 0.002). The mean values before and after the fast were all in
the norm range.
Fig 5. Fasting-induced changes in lipid metabolism.
https://doi.org/10.1371/journal.pone.0209353.g005
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Inflammatory biomarkers
The inflammatory biomarkers CRP and ESR were analysed. The mean values at baseline and
at the end were all in norm range (<5.0 mg/L). CRP raised significantly during fasting (fasting
Fig 6. Changes of blood glucose (A) and glycated haemoglobin (HbA1c) (B). The panel A was split for gender to increase the readability of the figure.
https://doi.org/10.1371/journal.pone.0209353.g006
Table 3. Blood cells pre- and post-fasting.
All
(n = 1422)
F5d
5±2 d
F10d
10±2 d
F15d
15±2 d
F20d
20±2 d
p-values
pre post pre post pre post Pre post pre post fasting
inter-
vention
fasting
dura-
tion
group
sex fasting dura-
tion group-
by-fasting
inter-
vention
fasting
inter-
vention-
by-sex
Leukocytes, 103/
μl
5.9
±0.0
5.4
±0.0
5.9
±0.1
5.5
±0.1
6.0
±0.1
5.4
±0.1
6.0
±0.1
5.0
±0.1
5.7
±0.3
4.7
±0.2
<0.001 <0.001 0.18 <0.001 –
Erythrocytes,
106/μl
4.76
±0.01
4.82
±0.01
4.76
±0.02
4.82
±0.02
4.76
±0.02
4.81
±0.02
4.74
±0.03
4.81
±0.03
4.74
±0.07
4.86
±0.07
<0.001 0.96 <0.001 – 0.001
Haemoglobin,
mmol/L
8.9
±0.0
9.0
±0.0
8.9
±0.0
9.0
±0.0
8.9
±0.0
9.0
±0.0
8.9
±0.1
9.0
±0.0
8.7
±0.1
8.9
±0.1
<0.001 0.72 0.33 – <0.001
Haematocrit, % 42.2
±0.1
42.3
±0.1
42.2
±0.1
42.3
±0.1
42.3
±0.1
42.3
±0.1
42.2
±0.2
42.3
±0.2
41.8
±0.5
42.2
±0.5
0.74 0.83 0.06 – 0.02
MCV, fl 89.0
±0.1
88.0
±0.1
88.8
±0.2
87.9
±0.2
89.1
±0.2
88.0
±0.2
89.3
±0.3
88.0
±0.3
88.5
±0.9
87.0
±0.8
<0.001 0.001 <0.001 0.001 <0.001
MCH, pg 30.1
±0.1
30.1
±0.1
30.1
±0.1
30.1
±0.1
30.2
±0.1
30.2
±0.1
30.2
±0.1
30.1
±0.1
29.7
±0.3
29.7
±0.3
0.38 0.12 0.82 0.09 –
MCHC, g/dl 33.9
±0.0
34.2
±0.0
33.9
±0.0
34.2
±0.0
33.9
±0.0
34.3
±0.0
33.8
±0.1
34.2
±0.1
33.6
±0.2
34.0
±0.1
<0.001 0.80 0.11 – 0.004
Thrombocytes,
103/μl
244.1
±1.5
237.5
±1.5
242.6
±2.2
239.2
±2.2
245.9
±2.5
238.9
±2.6
243.9
±3.9
230.6
±4.1
245.6
±11.4
224.4
±11.4
<0.001 <0.001 0.03 <0.001 <0.001
Values are shown as mean±SEM for all of the groups with different fasting lengths. P-values were calculated for the effects of fasting intervention as well as the effects of
the fasting length (fasting duration group) and gender (sex). Interactions between fasting intervention by fasting duration group (fasting duration group-by-fasting
intervention) and fasting intervention by gender (fasting intervention-by-sex) are shown.
MCV, mean cell volume; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration.
https://doi.org/10.1371/journal.pone.0209353.t003
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intervention: p<0.001). There was no difference between groups and gender. ESR after 1 and
2 hours decreased significantly (fasting intervention: each p<0.001) and the groups with lon-
ger fasting periods displayed stronger reductions (fasting duration group-by-fasting interven-
tion: each p<0.001).
Table 4. Blood parameters pre- and post-fasting.
All
(n = 1422)
F5d
5±2 d
F10d
10±2 d
F15d
15±2 d
F20d
20±2 d
p-values
pre post pre post pre post Pre post pre post fasting
inter-
vention
fasting
dura-
tion
group
sex fasting dura-
tion group-
by-fasting
inter-
vention
fasting
inter-
vention-
by-sex
INR 0.99
±0.00
1.08
±0.00
0.98
±0.00
1.06
±0.00
0.99
±0.01
1.09
±0.01
0.99
±0.02
1.11
±0.02
0.98
±0.01
1.10
±0.02
<0.001 <0.001 0.84 <0.001 –
Quick, % 104.3
±0.3
91.4
±0.3
104.2
±0.5
92.9
±0.4
104.0
±0.6
90.6
±0.5
105.6
±1.0
89.1
±0.9
104.1
±1.2
88.3
±1.9
<0.001 <0.001 0.33 <0.001 0.005
PTT, sec 31.1
±0.1
32.7
±0.1
31.1
±0.1
32.4
±0.1
31.0
±0.1
32.8
±0.2
31.2
±0.2
33.7
±0.3
31.4
±0.4
32.9
±0.5
<0.001 <0.001 0.88 <0.001 –
GOT, μkat/L 0.4
±0.0
0.6
±0.0
0.4
±0.0
0.6
±0.0
0.4
±0.0
0.6
±0.0
0.4
±0.0
0.6
±0.0
0.4
±0.0
0.7
±0.0
<0.001 0.73 0.007 – <0.001
GPT, μkat/L 0.5
±0.0
0.7
±0.0
0.5
±0.0
0.6
±0.0
0.5
±0.0
0.7
±0.0
0.5
±0.0
0.7
±0.0
0.6
±0.0
0.8
±0.1
<0.001 0.07 0.65 0.10 –
GGT, μkat/L 0.6
±0.0
0.4
±0.0
0.5
±0.0
0.4
±0.0
0.6
±0.1
0.4
±0.0
0.6
±0.1
0.4
±0.0
0.5
±0.1
0.4
±0.01
<0.001 <0.001 0.18 <0.001 <0.001
AP, μkat/L 1.1
±0.0
1.0
±0.0
1.0
±0.0
1.0
±0.0
1.1
±0.0
1.1
±0.0
1.1
±0.0
1.0
±0.0
1.2
±0.1
1.1
±0.1
<0.001 <0.001 0.003 <0.001 0.002
CRP, mg/L 2.85
±0.14
4.30
±0.20
2.49
±0.19
4.11
±0.27
3.02
±0.28
4.35
±0.36
3.37
±0.32
4.74
±0.63
4.08
±0.67
4.67
±0.82
0.001 0.97 0.99 0.81 0.53
ESR 1h 11.6
±0.2
11.4
±0.2
10.9
±0.3
11.7
±0.3
11.8
±0.4
11.5
±0.4
12.8
±0.7
10.6
±0.6
15.1
±1.6
10.2
±1.4
<0.001 <0.001 0.002 <0.001 <0.001
ESR 2h 21.7
±0.4
21.3
±0.4
20.4
±0.5
21.8
±0.5
22.1
±0.6
21.4
±0.6
23.9
±1.1
19.7
±1.0
28.2
±2.8
20.1
±2.4
<0.001 <0.001 <0.001 <0.001 <0.001
Uric acid,
μmol/L
338.1
±2.3
495.2
±4.4
334.0
±3.3
481.1
±6.0
339.2
±3.8
505.5
±7.5
345.3
±6.4
513.0
±13.5
355.9
±12.8
505.4
±30.6
<0.001 0.01 <0.001 0.01 <0.001
Urea, mmol/
L
4.7
±0.0
3.1
±0.0
4.6
±0.1
3.3
±0.1
4.7
±0.1
3.0
±0.1
4.7
±0.1
2.7
±0.1
5.1
±0.3
2.8
±0.3
<0.001 <0.001 <0.001 <0.001 <0.001
Creatinine,
μmol/L
71.92
±0.40
76.43
±0.54
72.53
±0.58
76.45
±0.76
71.88
±0.68
76.88
±1.00
69.86
±0.98
74.98
±1.21
72.27
±2.53
77.17
±3.13
<0.001 0.34 <0.001 – <0.001
Na,mmol/L 140.1
±0.1
138.7
±0.1
140.0
±0.1
138.4
±0.1
140.1
±0.1
138.8
±0.1
139.8
±0.3
139.2
±0.2
141.0
±0.33
139.9
±0.4
<0.001 <0.001 0.37 0.003 –
K, mmol/L 4.4
±0.0
4.4
±0.0
4.4
±0.0
4.4
±0.0
4.4
±0.0
4.4
±0.0
4.3
±0.0
4.4
±0.0
4.4
±0.1
4.4
±0.1
0.001 0.74 <0.001 – 0.008
Ca, mmol/L 2.32
±0.00
2.38
±0.00
2.33
±0.00
2.36
±0.00
2.32
±0.00
2.39
±0.00
2.32
±0.01
2.39
±0.01
2.33
±0.02
2.40
±0.02
<0.001 <0.001 0.14 <0.001 –
Mg, mmol/L 0.86
±0.00
0.87
±0.00
0.87
±0.00
0.89
±0.00
0.87
±0.00
0.87
±0.00
0.85
±0.00
0.86
±0.01
0.86
±0.01
0.85
±0.01
0.09 <0.001 <0.001 <0.001 <0.001
Values are shown as mean±SEM for all of the groups with different fasting lengths. P-values were calculated for the effects of fasting (fasting intervention) as well as the
effects of the fasting length (fasting duration group) and gender (sex). Interactions between fasting intervention by fasting duration group (fasting duration group-by-
fasting intervention) and fasting intervention by gender (fasting intervention-by-sex) are shown.
INR, international normalized ratio; PTT, partial thromboplastin time; GOT, serum glutamic oxaloacetic transaminase; GPT, serum glutamate pyruvate transaminase;
GGT, serum gamma-glutamyl transferase; AP, alkaline phosphatase; CRP, C-reactive protein; ESR 1h, erythrocyte sedimentation rate after 1 hour; ESR 2h, erythrocyte
sedimentation rate after 2 hours; Na, sodium; K, potassium; Ca, calcium, Mg, magnesium
https://doi.org/10.1371/journal.pone.0209353.t004
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Renal function and uric acid
Uric acid levels, as well as renal function as reflected by urea and creatinine values, are given in
Table 4. A significant increase of blood uric acid was observed (338.1±2.3 to 495.2±4.4 μmol/
L) (fasting intervention: p<0.001). The highest uric acid level was measured in F15d. Urea
concentrations decreased significantly in all groups (fasting intervention: p<0.001), but the
decrease was stronger in the groups with longer fasting periods (fasting duration group-by-
fasting intervention: p<0.001). Creatinine levels increased significantly (fasting intervention:
p<0.001) with differences between the sexes (fasting intervention-by-sex: p<0.001) but with-
out differences between groups.
Electrolytes
Sodium concentrations remained in norm range but showed a significant reduction (fasting
intervention: p<0.001) from a mean of 140.1±0.1 to 138.7±0.1 mmol/L. Calcium levels
increased significantly (fasting intervention: p<0.001), with an effect of groups (fasting dura-
tion group-by-fasting intervention: p<0.001) but not of gender. Potassium showed a reduction
during fasting (fasting intervention: p = 0.001) and magnesium levels remained stable. All val-
ues pre- and post-fasting remained in norm range.
Discussion
The present prospective observational study systematically investigated for the first time the
effects of long periods of Buchinger fasting within a specialized clinic in a cohort of 1422 sub-
jects. The results showed that this type of fasting from 4 to 21 days is safe and well tolerated.
Furthermore, it led to enhancement of emotional and physical well-being and improvement of
relevant cardiovascular risk factors and subjective health complaints.
Fasting resulted as expected in marked weight loss with reduction of abdominal circumfer-
ence, which was more pronounced in the groups who fasted longer. Thus it can be assumed
that preferentially visceral adipose tissue was reduced with weight loss [40]. Of note, no partic-
ular rebound in weight gain has been shown after repeated cycles of Buchinger fasting in a pre-
vious study [38, 39].
Blood pressure showed a significant decrease, whereby mean values did not fall below the
lower norm range, indicating a floor effect. Accordingly, serious hypotensive complications
were not reported. Blood pressure reduction might be triggered by factors such as the increase
of parasympathetic activity due to the release of brain-derived neurotrophic factor (BDNF) [2,
41, 42], increased renal Na excretion [43] and enhanced receptor sensitivity of natriuretic pep-
tides and insulin [44]. Earlier studies on zero calorie diets and very-low-calorie diets (VLCD)
[45–47]–and more recently in smaller studies on Buchinger fasting [33, 34] and water fasting
[48]–also described this blood pressure-reducing effect.
We further found decreases in blood lipid levels following the fasting periods: TG levels as
well as TC and LDL-C decreased significantly in all groups. Glucose levels and HbA1c
decreased also significantly which points out to a positive effect of fasting on glucoregulation.
It was also found in two previous smaller studies using Buchinger fasting [49, 50].
Altogether, the positive impact of periodic Buchinger fasting on the above mentioned
parameters suggests a general cardioprotective effect that has also been shown in IF [51].
The continuous increase in emotional as well as physical well-being was evident across all
groups of different fasting period lengths. This is an important component to increase compli-
ance and has been reported in earlier studies based on daily mood ratings [26, 52, 53]. Weight
loss, especially in obese subjects, is linked with mood improvement in many studies [54]. The
G-to-K switch has been shown in IF to lead to enhanced performance in cognition, mood,
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motor and autonomic nervous system function [2, 55]. In IF and CR this is linked to the
release of BDNF [51, 56]. BDNF, associated with neurogenesis and neuron protection,
enhances the growth and survival of serotonin neurons [51, 57]. Furthermore, the reduction of
insulin and leptin levels appears to act on the hypothalamic-pituitary-adrenal axis, thereby
impacting mood positively [58]. Endogenous opioid (β-endorphin) could also contribute to
well-being, as documented in a 10-day fasting trial in men [59]. In our study, the reported
improvement of a major health complaint, often accompanied by pain relief, could possibly
contribute to the increase of well-being. Moreover, it appears likely that a successful comple-
tion of a longer fasting period improves the feeling of self-efficacy, thereby enhancing subjec-
tive well-being [37]. It has been reported that short fasting periods of two days, as well as
alternate-day fasting, are associated with the feeling of hunger [60–62]. This seems to be an
obstacle to patient compliance [61, 62]. In contrast, hunger was not reported by 93% of the
subjects in our study, which often surprised them positively. This possibly contributed to
enhanced well-being.
As expected, we observed a significant increase in urinary ketone bodies excretion up to a
maximum level that was similar in all groups. This suggests that in 5 days a plateau was reached.
Ketosis and IMS was achieved, although Buchinger fasting provides small quantities of fruit juices
and some honey, providing up to 25–35 g carbohydrates/day. Experimental research points to
ketosis as the trigger of beneficial effects on brain and neurological diseases [2]. Daily time-
restricted feeding causing IMS ameliorates anxiety-like behaviour in mice [63]. IMS enhances also
structural and functional synaptic plasticity, cognition and neuronal stress response [64].
In our cohort, no fatal or life-threatening event occurred. Self-reported mild symptoms
were observed mainly in the first days and disappeared either spontaneously or with natural
remedies. Adverse effects were observed in 0.7% of subjects. Only two subjects had to interrupt
the fasting. Adverse effects have also been mentioned in other studies [34, 65].
A recent publication that analysed retrospectively water-only fasting data found relatively
more adverse effects, e. g. nausea, presyncope, dyspepsia, vomiting and palpitations [66],
which we observed only in single cases. The use of different methodologies to assess and char-
acterise AE limits the comparison with our study, which was prospective. Nevertheless, it
could be possible that the supplementation with juices and soups, which slows down initial
protein catabolism [67], enhances tolerability by modulating the onset of ketosis.
As already mentioned, we observed a subjective improvement in 85% of cases of a major
health complaint. This documents within the limitations of a non-confirmatory study design
the therapeutic effectiveness of Buchinger periodic fasting.
To assess further therapeutic effects of fasting, as well as the safety of this procedure, we per-
formed extended laboratory analysis. Within the blood count leukocytes and thrombocytes
decreased significantly but not below norm range. In humans after CR as well as in mice fed
with cycles of a low calorie fasting mimicking diet, a drop in leukocytes count was followed by
an increase in hematopoietic, mesenchymal stem and progenitor cells in the bone marrow.
This was associated with the regeneration of all blood cell types and haemoglobin upon refeed-
ing [4, 19]. We cannot extrapolate from our data whether this regeneration applies also to fast-
ing in humans.
The increase in INR values was significant and more marked in the groups who fasted lon-
ger. Bleeding time (PTT) was also increased. The increase in INR is well-known [68, 69] and
can be relevant for anticoagulated patients. During fasting they should be monitored and their
medication adapted.
GOT and GPT levels showed a significant increase within the norm range. GGT instead,
dropped significantly and stronger in the groups who fasted longer. A zero-calorie diet in 88
obese people for a duration of up to 35 days showed an increased activity of the GOT and
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GPT, with a peak in the 3rd fasting week [25]. This moderate increase was explained by the
enhanced transamination processes in the course of fasting. An initial overload of liver detoxi-
fying activity could be postulated and does not seem to have been deleterious effects, since
GGT levels decreased and physical well-being increased steadily.
CRP values for all groups showed a significant increase within the norm range. A similar
mild CRP increase was explained by the transient increase in circulating levels of catechol-
amines [34]. In a recent study, the modulation of CRP levels was linked to changes in lipid pro-
files and associated to cardiovascular outcomes [70]. ESR after 1 h and 2 h decreased
significantly. Periodic fasting has been shown to clinically improve symptoms of rheumatoid
arthritis, suggesting decreased inflammatory processes [71]. IF boosts levels of antioxidants
and reduces levels of pro-inflammatory cytokines TNF-α, IL-1β and IL-6 [72]. Serum markers
of oxidative damage and inflammation are reduced in asthma patients maintained on an alter-
nate day fast [62]. Moreover, the reduction of abdominal circumference which was significant
in our study is also associated with a decrease in pro-inflammatory activity [73].
We observed an increase of uric acid in all groups, with a lower value in F20d than in F15d,
suggesting that the peak of uric acid concentration was overwhelmed after 15 days. This corre-
sponds to previous observations from a zero-calorie diet [45, 74]. The increase of uric acid
concentrations that exceeded the norm range, interestingly caused only one incidence of gout
attack in a 72-year-old obese man, treated for hyperuricemia and gout previous to fasting.
The increased concentration of blood uric acid is due to a slight initial increase in protein
catabolism, but above all is related to retention caused by competitive tubular secretion with
ketone bodies. The latter are preferentially secreted during fasting.
Uric acid has a known antioxidant activity and is a potent scavenger of free radicals in
blood plasma [75, 76]. Given that fasting is the product of a long evolutionary survival strategy,
the antioxidant power of uric acid should be taken into consideration.
A significant reduction in urea as well as a significant increase in creatinine was observed,
both remaining in norm range. This has been previously demonstrated in obese persons
undergoing prolonged periods of a zero-calorie diet [45].
We did not observe any renal dysfunction in our cohort such as has been described in cases
of extracellular hypovolemia [77]. This is probably explained by the fact that the subjects were
asked to drink 3 L of water per day.
Sodium, potassium, calcium and magnesium were in norm range at the beginning and the
end of the fast. They remained stable despite a slight elevation in calcium and slight decrease
in sodium levels. Enhanced natriuresis has been described in association with ketosuria in the
first phase of fasting, diminishing when ammonium, a metabolite of kidney gluconeogenesis,
replaces sodium as accompanying cation [43, 47]. We registered six cases of mild hyponatre-
mia in the course of the fast, with the lowest sodium level of 127 mmol/L. They were all non-
serious and were normalized by the administration of sodium chloride.
There are some limitations related to our study. First, this was an observational cohort
study with its well-known restrictions regarding interpretation of efficacy. Second, our find-
ings are specific for BWC and may not be applicable for other institutions specialised in fast-
ing, or for persons fasting without medical supervision, or outside of facilities specialized in
fasting treatments. Third, data assessment and data entry was not blinded and was performed
by the staff of the BWC.
Conclusions
In conclusion, this one-year observational study demonstrates the safety of a periodic Buchin-
ger fast of between 4 and 21 days, as well as its beneficial effects on health and well-being.
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Periodic fasting led to marked weight loss and improvements in several cardiovascular risk fac-
tors, such as overweight, abdominal circumference and blood pressure. It was accompanied by
normalization of numerous blood parameters and led to pronounced improvement of the
major health complaint in most participants. Importantly, periodic Buchinger fasting was not
linked to relevant perception of hunger. On the contrary, it was subjectively experienced as
enjoyable, which is an important factor for compliance.
Further studies should evaluate the long-term specific health-related preventive and thera-
peutic effects of periodic fasting.
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